This is an unwarranted slight on CfH, which _did_ produce lots of useful work.
Unfortunately it was far too ambitious and effectively killed private development of healthcare software for the U.K. market in the process, making (for an example relevant to one area of my expertise) dose-based eprescribing a pipe dream despite having produced a ton of useful standards.
Unfortunately it was far too ambitious and effectively killed private development of healthcare software for the U.K. market in the process, making (for an example relevant to one area of my expertise) dose-based eprescribing a pipe dream despite having produced a ton of useful standards.